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Abstract 
Wound healing entails a series of complex stages where various cellular components of skin 
play a key role such as fibroblasts, keratinocytes, immune cells, endothelial cells, and 
extracellular matrix. The normal healing process can be divided into three distinctive phases: 
1) inflammation, 2) proliferation and 3) maturation. Wounds which have failed to repair over 
a Period of three months are characterized as a chronic wound. In India, high costs of 
treatment can persuade patients from seeking proper care, which leads to the development of 
complex and/or chronic wounds. There are several treatments being investigated, such as stem 
cell therapy, delivery of bioactive compounds (e.g., growth factors, cytokines, Peptides) to the 
wound site by encapsulating into microbeads. Macrophages play important role in modulation 
of inflammatory response. Among two phenotypes of macrophage (e.g., M1 and M2), the M2 
phenotype has a significant role in signalling of subsequent phases of wound healing. The aim 
of this project was the development of polysaccharide based microbeads, which would 
provide an anti-inflammatory environment to encapsulated macrophages.  It was hypothesized 
that in presence of anti-inflammatory environment, un-activated macrophages may polarize to 
M2 phenotype and help in chronic wound healing by secreting anti-inflammatory cytokines 
and various growth factors in a sustainable and continuous manner. Pectin and 
polygalacturonic were chosen to develop macrophage encapsulated microbead system. 
Experimental results depicted that Pectin and PgA based microbeads could be used in this 
purpose since it was observed that these polymers are highly hemocompatible and do not 
have any cytotoxic effect on encapsulated cells. Encapsulated macrophages remained viable 
inside the beads for more than a week. Additionally, these beads promoted proliferation of 
macrophages. At the end morphological study showed that un-activated macrophages were 
polarized to M2 phenotype (macrophages attained an elongated structure) when seeded on 
Pectin and PgA based film. The polarization of un-activated macrophages to M2 phenotype in 
presence of anti-inflammatory environment inside the microbeads seems an effective strategy 
which might help further to treat chronic wounds within a shorter time span.  
Keywords: Macrophages; Wound healing; Chronic wound; M1 phenotype; M2 phenotype;   
Pro-inflammatory; Anti-inflammatory; Cytokines; Pectin; Polygalacturonic acid; 
Microbeads; Encapsulation 
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Chapter 1 
Introduction 
1.1. Chronic Wound 
 
Wounds, which fail to get repaired through the orderly process of healing within a 
stipulated timeframe, are characterized as chronic wounds. Even after three months, 
wound bed lacks to produce structural and functional integrity through healing, in the case 
of chronic wound [1]. Most of the time presence of a raised, hyperproliferative, yet non-
advancing characteristics of wound area helps to identify chronic wounds. One of the 
major reasons for this failure to heal is uncontrolled and self-sustaining inflammatory 
environment. Moreover, wound healing is an inherently complex procedure, which is the 
main cause of the failure of monotherapies [2]. The local wound environment remains 
mostly rich in pro-inflammatory cytokines. Moreover, this leads to an imbalanced 
enzymatic milieu consisting of an excess of matrix metalloproteases (MMP) and reduces 
their inhibitors, which lead to the destruction of the extracellular matrix (ECM). Thus, the 
healing process is delayed due to profound inflammation and this can be depicted as a 
hallmark of chronic wounds. Understanding of molecular mechanism of wound healing is 
necessary to control this prolonged inflammation, also to repair tissue within stipulated 
time. Recent scientific advancement has come up various new approaches to cure this 
problem of chronic wound like the application of akin substitutes, growth factors and stem 
cell-based therapy [3]. 
 
1.2. Wound Healing 
 
Wound healing is a complex process of revitalization of impaired tissue layer and 
damaged cellular structure [4]. There are six stages of wound healing according to the 
study published in the World Journal of Surgery, each of which is very crucial and 
depends on one another in order to completely heal a wound. 
 
a) Rapid hemostasis: This is the first stage of healing where bleeding is terminated, 
because of vasoconstriction.    
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b) Inflammation: Inflammation acts as an alert system. Beyond that, it also helps the 
system to lead the healthy cells, where those cells should be headed next. Hence, 
inflammation is one of the vital stages of wound healing. However, prolonged 
inflammation can actually hinder the regeneration process. 
c) Proliferation and migration: During inflammation, various stimuli causes 
migration and proliferation of various cells engaged in the healing process. 
Migration is a coordinated process, which involves the movement of cells in a 
specific order and proliferation is similar to hemostasis because in this case cells 
toil to constrict the blood vessels. 
d) Angiogenesis: Body starts to rebuild tissue once the bleeding is under control. 
Meanwhile, new blood vessel formation occurs, which process known as 
angiogenesis. This process helps to replace damaged arteries and veins by 
following a complex mechanism.  
e) Reepithelialization: Once veins have regrown, reepithelization occurs. This 
process creates several layers which prevent fluid loss from the wound bed and 
offers protection. 
f) Synthesis: This is the last step of wound healing but it often occurs simultaneously 
with other steps of healing. Here, certain proteins help in clotting of blood which is 
followed by formation of new veins and skin due to angiogenesis and remodeling 
of collagen respectively. 
 
Furthermore, each of these six stages is very crucial and also interdependent on each other 
in order to heal a wound completely [5]. Therefore, generation of any effective therapy for 
pathological tissue repair requires a complete understanding of those mechanisms, which 
control these above-mentioned six stages of wound healing [3]. 
 
1.3. Factors Affecting Wound Healing 
 
Patients in India do not receive proper care due to the limitation of resources and huge 
expense of medical treatments. This critical condition also adds to the development of 
chronic wounds. Healthcare costs have been steadily increasing worldwide. It has been 
reported, that in India funding in public healthcare is not more than 5% of the annual GDP 
(gross domestic product). Hence, a majority of the population (approximately 80%) met 
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healthcare costs from out-of-pocket payments [6]. Three major causes of this chronic 
wound development are deficient healthcare services, insufficient workforce, inadequate 
and low-grade health care infrastructure [7]. Apart from these, comorbidities such as 
Peripheral vascular disease (PVD) and diabetes mellitus (DM) alter the wound healing 
process; act as an additional factor in the development of a chronic wound. Diabetes 
affects wound healing through the development of ischemia, decreased inflammatory 
responses, loss of protective sensations due to neuropathy, and increased the threat of 
infection. Whereas PVD can cause morbidity and mortality, especially in aged and 
diabetic populations [6].  
Systemic factors that have influencing effect on wound healing are [8]:  
 Diabetes 
 Age 
 Sex Hormones in Aged Individuals  
 Stress  
 Obesity 
 Medications (e.g., Glucocorticoid Steroids, Non-steroidal Anti-inflammatory 
Drugs, Chemotherapeutic Drugs)  
 Smoking  
 Alcohol Consumption 
 Poor circulation and Perfusion 
 Venous stasis 
 Infection 
 Trauma/repetitive forces 
 Pressure 
 Immunosuppression 
 Malnutrition 
 
Apart from these external factors, various cells are responsible for proper wound healing 
such as macrophages, neutrophils, keratinocytes, endothelial cells, fibroblasts, and 
lymphocytes. If these cells do not carry out their functions properly in a harmonic manner, 
healing does not follow its stages in correct order. Multiple local, as well as systemic 
factors, cause impaired wound healing by affecting one or more individual phases [8]. 
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1.4. Objectives 
 
II. Fabrication of a low-cost experimental setup, to produce microbeads for cell 
encapsulation. 
• Optimization of the rotation speed of centrifuge. 
• Optimization of the polymer composition, suitable for cell encapsulation. 
III. Development of biocompatible microbeads with anti-inflammatory properties. 
• Determination of hemocompatibility of selected polymer(s). 
• Determination of post-encapsulation cytotoxicity level inside microbeads. 
IV. Encapsulation of macrophages in Pectin and PgA based microbeads. 
• Determination of cell viability inside microbeads. 
V. Evaluation of the efficiency of microbeads in the polarization of un-activated 
macrophages to elongated M2 phenotype.
 5 
Chapter 2 
Review of Literature 
2.1. Application of Stem Cells in Chronic Wound Healing  
 
Current treatments available for chronic wound healing such as special type of wound 
dressing, hydrogels or scaffold-mediated delivery of growth factors (e.g., TGF-β, bFGF), 
have not yet achieved the desired results. Therefore, more effective therapeutic approaches 
are required. It has been reposted that wound healing can be regulated by bone marrow-
derived mesenchymal stem cells (BMSCs) through a series of paracrine growth factors 
[9]. BMSCs can be induced to differentiate into effector cells involved in wound healing, 
such as keratinocytes, fibroblasts, and endothelial cells. Thus, stem cells help to accelerate 
wound closure and enhance vascularization, granulation, reepithelialization, and tissue 
formation [10]. Recent histology and immunohistochemistry results have shown that 
hydrogel laden BMSCs can be a promising therapeutic strategy for the management of 
diabetic ulcers. This promotes angiogenesis, extracellular matrix (ECM) secretion, 
granulation tissue formation, reepithelialization, rapid wound bed contraction, and 
regeneration of sebaceous glands as well as hair follicles. Thus, it contributes to rapid skin 
wound healing of diabetic patients with reduced scar formation. This series of beneficial 
biological effects occur because it enhances secretion of TGF-β and bFGF. These results 
have provided a reliable guidance in clinical settings for the treatment of diabetic foot 
ulcer [11]. Several groups of scientists have conducted various experiments to define 
optimum time required for these steps and suitable route of administration. However, to 
define these we need to understand MSCs mechanism of action (MOA) in repairing of 
tissue and its regeneration process. Large-scale multicenter trials need to be performed to 
test MSC-based therapy stringently, to completely validate this for any commercial 
purpose [12]. MSCs have shown highest efficiency in promotion of chronic wound 
healing as compared to other therapies. Further, comparative studies have demonstrated 
that intradermal injection is more effective than systemic injection of MSCs in chronic 
wound healing purpose. Intradermal injection of MSCs can promote rapid cell 
proliferation, granulation tissue formation, angiogenesis and collagen fiber synthesis [13]. 
Compared to either intravenous or topical administration of BMSCs, BMSC aggregate 
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transplantation showed better neo-vascularization and more regular collagen deposition on 
acute cutaneous wound model, thus bringing higher regenerative and healing efficacy. The 
mechanism behind this may be better regulation of inflammatory process due to BMSC 
aggregate engraftment [14]. It has been demonstrated by various clinical trials that 
mesenchymal stem cells (MSCs) not only help to decrease inflammatory response, 
promote angiogenesis, enhance closure of wound but also increase tensile strength within 
the wound. However, the regenerative ability of MSCs in human wounds has not yet been 
tested, because of various limitations in human studies. Further research is required to 
propose an optimized method to isolate, characterize and harvest stem cells indisputably 
[12].  
 
2.2. Application of Peptides in Chronic Wound Healing 
 
Other than administration of stem cells, rapid wound healing can be achieved by using 
camel milk Peptide (CMP) as a therapeutic agent. It is an effective immune stimulant and 
antioxidant, which induces oxidative stability by enhancing the activity of some major 
antioxidant enzymes such as catalase (CAT), glutathione (GSH), and superoxide 
dismutase (SOD). Thus, CMP speeds up wound healing by acting as a potential adjuvant 
in improving chronic wound healing in those with diabetic conditions [15].  
 
2.3. Application of Peptides in Chronic Wound Healing 
 
A major component of most skin substitutes is collagen because of its bioactive cues and 
specific structure. Thus, either collagen or collagen mimetic protein can be used to treat 
the chronic wound. Scl2GFPGER, a collagen mimetic protein, can be encapsulated in a 
bioactive hydrogel, to promote active wound healing. Further, a redesigned Scl2GFPGER, 
engineered collagen (eColGFPGER), reduces steric hindrance of integrin-binding motifs. 
Thus, it increases the overall stability of the triple-helical backbone which leads to 
increase in cell adhesion to substrates. Collagen-mimetic wound dressing Permits 
controlled modulation of cellular interactions and degradation rate without affecting other 
physical properties. Moreover, a bioactive dressing can be provided by its fabrication into 
uniform hydrogel microspheres which can readily conform to irregular wounds [16]. 
Calcium alginate is a natural polymer which helps in wound healing, which possesses 
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faster epithelialization though it has a milder inflammation effect while implemented 
inside the system. Calcium alginate also has excellent cytocompatibility as well as 
histocompatibility  
characteristics and it acts as a promoter of diabetic wound healing by attenuating 
inflammatory reaction and increasing the contraction of wounds. It increases the levels of 
type I collagen and hydroxyproline which leads to a significant increase in the tensile 
strength of wound. All in all, the stimulation of expression of collagen I and elevation of 
collagen I to III ratios to a large extent are major causes of this accelerating effect of 
calcium alginate. Thus calcium alginate based dressing provides a potential strat¬egy of 
wound healing and easily used way to ameliorate the foot ulceration by preventing limb 
amputation in diabetic populations [17]. Other than natural polymers some synthetic 
polymers also help in wound healing process. Prolonged insulin release to the target site 
can be provided by insulin-secreting cells encapsulated into Pectin-GDA hydrogel 
microsphere. The basis of this prolonged release is the prevention of immune clearance 
and migration because of microsphere encapsulation. Thus keeping the microencapsulated 
cells in the desired location. This combination of insulin-releasing cells and Pectin-GDA 
hydrogel microencapsulation is a novel method for delivering a steady and constant dose 
of insulin to wound site [18]. Pectin is the major component of plant cell walls which 
displays diverse biological activities such as immunomodulation. The macromolecule of 
Pectin contains fragments of both linear and branched regions of polysaccharides such as 
homo-galacturonan, apio-galacturonan, xylo-galacturonan, and rhamno-galacturonan-I. 
These structural features of Pectin are key to its effect on the immune system. The 
backbone of Pectin macromolecule has immunosuppressive activity. Macrophage activity 
can be decreased and delayed-type hypersensitivity reaction can be inhibited by the Pectin 
containing greater than 80% galacturonic acid residue. Whereas biphasic 
immunomodulatory action can be attained by the help of branched galacturonan fragments 
[19]. Pectic acid is also known as Polygalacturonic acid have anti-inflammatory property 
besides its bioadhesive property. Furthermore, in this anti-inflammatory environment 
macrophages might have a higher probability to polarize in M2 phenotype. Hence, Pectin 
or Pectic acid can be used to treat chronic wounds by encapsulating growth factors, 
signaling molecules, stem cells or macrophages and delivering those bioactive factors at 
the target site [20]. 
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Table 2.1: General therapeutic modalities and their mechanism of action (MOA) for 
chronic wound healing (adapted from, [12]). 
Treatment Proposed Mechanism(s) of Action 
Debridement (variety of 
methods) 
a) Surgical 
b) Chemical 
Removes foreign debris and devitalized or 
contaminated tissues from the wound bed. 
Compression Decreases venous backflow and capillary leakage. 
Negative Pressure 
Removes exudate, reduces edema, increases local 
Perfusion, decreases bacterial count, and enhances 
granulation tissue formation. 
Electrical Stimulation 
May promote migration of various cell types to the 
wound by reducing the size of venous leg ulcer. 
Hyperbaric oxygen therapy 
(HBOT) 
Improves neovascularization, reduces production 
of pro-inflammatory cytokines, and increases 
synthesis of GFs and collagen. 
Lasers, phototherapy, 
shockwaves,  
and ultrasound 
 
Decreases inflammatory cells, increases fibroblast 
proliferation, stimulates angiogenesis, promotes 
the formation of granulation tissue, and increases 
collagen synthesis. 
Silver Antimicrobial 
Cadexomer iodine Antimicrobial 
Others (povidone-iodine, 
Peroxide preparations, 
ethacridine lactate, or 
chlorhexidine) 
Antimicrobial 
Dressings (alginate, foam  
dressing, hydrocolloids, 
hydrogels) 
Provides appropriate moist wound environment, 
which contributes to faster wound reepithelization. 
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2.4. Application of Growth Factors in Chronic Wound Healing 
 
Several growth factors (GFs) help in the rapid healing of wound bed such as acidic 
Fibroblast growth factor (aFGF), Platelet-derived growth factor (PDGF) (Table 1). 
Furthermore, administration of aFGF on a diabetic patient, significantly improve healing 
of wound bed. The therapeutic application of aFGF has its own limitation of shorter 
halflife and very low efficiency of delivery. Transactivator of transcription protein (TAT) 
mediated delivery of aFGF helps to overcome this limitation.  Moreover, it helps in 
chronic wound healing by facilitating Penetration of aFGF through the epidermis. TAT 
has been tagged with this feature because it has a regulatory effect on expression of α-
SMA, restoration of TGF-β1 and TGF-βRII synthesis. This TAT-mediated aFGF delivery 
has the capability to prove itself as a less invasive and more efficient approach, in the case 
of type 1 diabetic patient (T1DM), having ulcers due to any physical damage or the 
diabetic condition [12]. Among T1DM patients, the major cause of delay in wound 
healing is decreased in the number of regulatory T cells (Treg), and cytokine such as 
interleukin 2 (IL-2). Prolonged inflammatory phase act as a hallmark in the case of 
chronic wounds such as diabetic foot ulcer. IL-2 topical cream can be beneficial in the 
treatment purpose of diabetic foot ulcer  
[21]. This is suitable for patients from any age group and background since much 
education or advice from expertise is not required in the application of the topical cream. 
Moreover, topical cream has its own benefits over intravenous treatment such as thin line 
chances of infection and allergic reactions. This treatment method also helps to protect 
skin from issues like dryness, by maintaining a moist environment around the wound bed. 
Other than this above-mentioned cytokine, IL-17 may have some regulatory functions in 
the healing of chronic wounds by influencing the differentiation of macrophages into 
CD11b+Ly6C+MHC Class II+ [22]. Other than aFGF, due to injury huge amount of 
degranulating platelets release PDGF during the early stage of injury [23]. Furthermore, 
the presence of PDGF has been observed in samples collected from the wound site of pig, 
murine and human [24]. It has been observed, that PDGF receptors are present in dermis 
whereas ligands are available in the epidermis. This observation suggests that PDGF and 
its receptor follows paracrine mechanism. Some experimental results have shown decrease 
in expression of PDGFs and its receptors during diabetic condition, which leads to the 
formation of the chronic wound [25]. This evidence suggests that a proper wound healing 
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requires a certain level of expression of this above-mentioned growth factor.  In addition 
to aFGF and PDGF, a considerable amount of Epidermal growth factor (EGF) and TGF 
was also present in wound fluid collected from burn injuries [26]. Further, studies have 
shown the key role of Heparin-binding EGF (HBEGF) in granulation tissue formation and 
reepithelialization. The highest amount of HB-EGF is present during the stage of the 
proliferation of keratinocytes [27]. 
 
Table 2.2: Growth factors and its role in wound healing (adapted from, [12]). 
Treatment Mechanism(s) of Action 
PDGF 
For diabetic foot ulcer (DFU), this provides a scaffold on which 
new cells can migrate and attach. 
bFGF 
This promotes the proliferation of fibroblasts and capillary 
formation and accelerates tissue regeneration. 
rhEGF 
For both DFU and venous chronic wounds. 
Increases granulation tissue formation and reduces wound and 
cellulitis in the surrounding area. 
 
 
2.5. Application of Cytokines in Chronic Wound Healing 
 
Cytokines are synthesized as well as secreted by various cell types present in our system. 
These are mainly small proteins or glycoproteins, which helps in regulation of various 
activities of the cell (e.g., growth and differentiation), matrix synthesis, migration of cells, 
and immune functions through binding to target cells with the help of specific receptors 
[28]. Wound healing is a complex process which follows the stages of inflammation after 
initial injury, tailed by cell proliferation and migration of parenchymal as well as 
mesenchymal cells, then production and deposition of extracellular matrix (ECM) [29]. If 
wound bed fails to follow this orderly process then fibrosis occurs. At the latter stage, 
cellular interaction takes place via a complex network of cytokines. This leads to immense 
remodeling and heightened production of ECM, followed by abnormal deposition in the 
tissue. Each and every cytokine have its own role in both promotion and inhibition of 
fibrogenesis. Progress in the understanding of the process, responsible for pathogenesis of 
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fibrosis, provides us the knowledge to generate inhibitors of these profibrogenic cytokines 
and GFs. Further, those inhibitors can play the role of novel therapeutic agents to control 
undesirable fibrosis [30]. Proinflammatory cytokines such as IL-6, IL-1α, IL-1β, TNF-α 
are upregulated during inflammatory phase [31]. A major source of these cytokines are 
macrophages and polymorphonuclear leukocytes. For normal repairing system of the 
wound, a balanced expression of these cytokines is required [32]. Other than 
proinflammatory cytokines, Anti-inflammatory cytokines such as IL-10 also have a 
significant role in the regulation of wound repair. IL-10 plays a significant role in limiting 
and terminating inflammatory response at the injury site and inhibits the formation of a 
scar. Apart from that, this cytokine has also shown key role in differentiation and growth 
of endothelial cells, immune cells, and keratinocytes. Experimental results suggest 
treatment with IL-10 results in scar-free healing [33]. 
 
Table 2.3: Effects of growth factors and cytokines in wound repair (adapted from, [34]). 
Process Growth Factors and/ or Cytokines Involved 
Neutrophil 
infiltration 
MCP-1, IL-8, IL-10, TGF-β 
Macrophage 
infiltration 
TGF-β, IL-10, MCP-1, MIP-1α 
Angiogenesis 
FGF2, VEGF-A, GM-CSF, PLGF, Angiopoietins, Cyr61, MCP-1, 
IL-8, IP-10, HGF 
Fibroplasia TGF-β, CTGF, IGFs, PDGF, GM-CSF 
Matrix deposition TGF-β, Activin, CTGF, Cyr61, NGF, IGF-1, FGF2 
Scarring IL-6, TGF-β, CTGF, IL-10, Activin, IGF-I  
Reepithelialization 
EGF, FGF2, FGF7, FGF10, IGFs, IL-6, TGF-β, IP-10, TGF-α, 
Activin, Leptin, HB-EGF, BMP-6, GM-CSF, NGF 
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2.6. Application of Macrophages in Chronic Wound Healing 
 
Macrophages are typically known for their role in immune defence mechanism and 
phagocytic capabilities. Recently, some well-established evidence have demonstrated 
heterogeneous characteristics of un-activated macrophages. One possible explanation 
could be the ability of un-activated macrophages to polarize into two different phenotypes 
(e.g., pro-inflammatory and anti-inflammatory) in response to the various 
microenvironmental stimulus. Activated macrophages which are polarized into anti-
inflammatory phenotypes, play a crucial role in wound healing [35]. Two well-known 
macrophage polarization process activates unactivated macrophages to  pro-inflammatory 
phenotype (M1), activated through classical pathway or anti-inflammatory/ wound healing 
phenotypes (M2a, M2b, M2c, M2d), by following alternative pathway, in response to 
various environmental stimuli  such as Interferon gamma (IFNγ) and Interleukin-4 (IL-4), 
respectively [36, 37]. 
 
 
 
Figure 2.1: Polarization of un-activated macrophages to M1 & M2 
phenotype (adapted from [38]). 
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The M1 phenotype induces production of pro-inflammatory cytokines such as IFN- γ, 
Interleukin-2 (IL-2), Tumor necrosis factor alpha (TNF-α) and some microbicidal agents 
like reactive oxygen species (ROS) and nitric oxide (NO) [38, 39]. On the other hand, in 
later stages of tissue repair and healing process M2 phenotype predominates by enhancing 
the secretion of anti-inflammatory cytokine Interleukin-10 (IL-10) and growth factors like 
vascular endothelial growth factors (VEGF) and transforming growth factor beta (TGFβ) 
[40]. M1 and M2 macrophages can be distinguished by examining the ratio of IL-12 and 
IL-10 [41]. Macrophage polarization is an important part of effective wound healing. Each 
phenotype of macrophages have its own distinct role in this healing process such as M2d 
phenotype has a critical role in angiogenesis during the healing process. Some 
transcription factors (TFs) play a key role in activation of macrophages, for example, IRF5 
TF activates un-activated macrophages into M1 phenotype and Jumonji domain 
containing-3-IRF4 is responsible for activation of M2 phenotype [35]. 
 
 
Figure 2.2: Macrophage polarization pathways (adapted from [35]). 
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The progress in the field of regenerative medicines and tissue engineering (TE) have made 
it possible to produce desired biomaterials, having tailored mechanical, physical, chemical 
and temporal characteristics required to interact with the host system. Such advancement 
in the functionality of biomaterials and understanding of macrophage response mechanism 
have made it possible to identify and select the suitable design of biomaterials, which can 
control response of host system. Thus, desired characteristics of biomaterials can help us 
to attain successful tissue engineering [42]. In this case of chronic wound healing, 
immune-informed biomaterials can be designed for sustainable release of some desired 
factors (e.g., IL-4, IL-10, steroids) to control the immune response. This strategy would 
help in the direct polarization of macrophages to wound healing phenotype by overcoming 
native signaling pathways [43, 44]. Incorporation of gene delivery vectors, small molecule 
drugs (e.g., steroids), desired cytokines producing cells (e.g., M2 phenotype of 
macrophage), growth factors (e.g., PDGF, aFGF), into a controlled systems could help in 
the release of single factor or multiple factors in a sustainable manner [44]. The selective 
polarization of macrophages requires complete understanding of biomaterial cues. 
Moreover, it will help us to design new generation ‘immuno-informed’ biomaterials to 
interact with the immune system as necessary for post-implantation macrophage response, 
in the case of chronic wound healing [42].  
 
2.7. Application of microencapsulation of cells in chronic 
wound healing 
 
Cell encapsulation for immune-isolation is a method, which enables the process of 
continuous and long-term delivery of therapeutic factors into a selected target tissue. The 
encapsulated cells help to produce and release therapeutic molecules when transplanted 
into the body [45]. The principle of cell encapsulation is the isolation of transplanted cells 
from its surrounding host immune system by enclosing them in a semipermeable 
polymeric matrix. The main purpose of this semipermeable membrane is to exclude 
harmful components of host immune system such as immunoglobulins, complement and 
immune cells to prevent immune rejection after transplantation into the host system. 
Furthermore, this semipermeable membrane also allows bi-directional diffusion of 
oxygen, nutrients, waste and the therapeutic products to maintain the encapsulated cells 
viably, healthy and functional. In addition to this, cell encapsulation offers an internal 
matrix to the cells that create a 3D microenvironment for the encapsulated. This internal 
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matrix act as a substitute for the ECM of native tissues, which is important to keep the 
encapsulated cells viable and functional [46]. Incorporation of immunomodulatory human 
mesenchymal stromal cells (hMSCs) has been Performed, in animal models to reduce 
secondary inflammatory responses. This therapeutic protocol can be useful for the 
treatment of spinal cord injury (SCI). Thus, limitations in direct hMSC implantation can 
be circumvented, in post-SCI treatment. Alginate microencapsulation is mostly used by a 
different group of scientists as an implantable vehicle for delivery of hMSCs to the wound 
bed. Encapsulated hMSCs remains viable and its secretory functions also do not get 
affected if the encapsulation is carried out in a proper manner. Further, modulation of the 
functions of inflammatory macrophages can be attained both in in-vitro and in-vivo, even 
if hMSC and macrophages are not in direct contact. Induction of hMSCs with anti-
inflammatory factors such as IL-4, enhance secretion of anti-inflammatory cytokines. 
Thus, this process helps to promote activation of more number of the M2 phenotype. In-
vitro, this was evident after observing a reduction in expression of iNOS by macrophages 
with a collateral increase in CD206, a marker for M2 macrophages [47]. 
 
2.8. Rationale of current study 
 
Procurement of macrophages from peripheral blood is much easier than the complex 
process of collection and processing of hMSCs. Moreover, efficient delivery of 
macrophages would also help to maintain a proper balance in between pro-inflammatory 
and anti-inflammatory environment by secreting desired cytokines and growth factor at 
the wound bed while applied in vivo. Major challenges in implementing such strategy are: 
prevention of macrophages from washing out from the site of injury and sustenance of M2 
phenotype over the period of healing. This limitation could be overcome by encapsulation 
of macrophages in micro-bead system. Further, use of such polymers which have anti-
inflammatory properties (e.g., pectin and PgA) might help us to achieve our goal, by 
polarizing macrophages to M2 phenotype. Those encapsulated M2 phenotypes would 
secrete anti-inflammatory cytokines (e.g., IL-10) and growth factors (e.g., VEGF) in a 
sustainable and controlled manner, which would speed up the healing process. Hence, we 
envisioned that the application of encapsulated macrophages could be used for rapid and 
scar free healing of chronic wounds. 
.
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Chapter 3 
Materials and Methods 
3.1. Materials  
 
Pectin, Calcium Chloride (Anhydrous) and Tween-80 were obtained from HiMedia. 
Polygalacturonic acid (PgA) was purchased from Sigma-Aldrich. 15 ml Falcon tube was 
purchased from Tarson and 1ml syringe (needle diameter 30 gauge) fabricated by the 
company Terumo, was bought from a local pharmacy. RAW 26.7 cell line was obtained 
from NCCS, Pune. Materials used in cell culture purpose such as Phosphate buffer saline 
(1X), DMEM cell culture media (Low glucose), Foetal bovine serum (FBS), Trypan blue 
(Powder), Antimitotic antibody, MTT (Thiazolyl Blue Tetrazolium Bromide) and Nitro 
Blue Tetrazolium Chloride (NBT) Dye were purchased from HiMedia. Lactate 
Dehydrogenase (LDH) Assay Kit was purchased from Accurex. Cell culture equipment 
such as T-25, T-75 Flasks, and cell scrapers were purchased from HiMedia.  
 
3.2. Fabrication of centrifuge tube-syringe setup  
 
Using driller machine, 20 centrifuge caps were holed as shown in fig. 2(a). Then holes 
were made on both sides of 1 ml syringe as shown in fig. 2(b). This was done for 20 
number of the 1 ml syringe. Then syringe was inserted into a hole made in centrifuge caps. 
At the end, centrifuge cap was inserted into centrifuge tube to make the complete setup as 
shown in fig. 2(c, d). 
 
  
 
 
 
 
a. b. 
Figure 3.1: Holes were made on (a) 15 ml centrifuge tube, and (b) 1 ml syringe (30G 
needle diameter) using driller, to fabricate a centrifuge tube-syringe setup to produce 
microbeads. 
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3.3. Experimental Setup 
 
In this novel, rotor based set-up, droplets were generated within the dripping regime at the 
micro-nozzle tip of a commercially available syringe. The syringe contains polymer 
solution and centrifuge tube contains CaCl2 solution. Therefore, the Pectin and PgA 
polymer droplets impact perpendicularly to the air–liquid meniscus inside the centrifuge 
tube. Gravity prevails to realign those centrifuge tubes in a vertical position when the rotor 
halts. Further processing (e.g., culturing or analysis) could be done once the Centrifuge 
tube-syringe setup is taken out from the rotor. Several nozzles could be operated on the 
same rotor simultaneously, due to the intrinsic rotational symmetry induced artificial 
gravity conditions (adapted from B.Tech thesis work conducted by Mr. Rahul Kumar at 
NIT- Rourkela, titled: Fabrication of micro-alginate beads under centrifugally induced 
artificial gravity conditions). 
c. d. 
Figure 3.2: Centrifuge tube-syringe setup (a) side view, and (b) top view. 
Figure 3.3: Schematic of the experimental setup consisting of centrifugal platform and 
centrifuge tube-syringe setup in a swinging bucket 
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3.4. Production of microbeads  
Microbeads were produced using various concentration of Polygalacturonic acid (PgA) 
and Pectin at a different proportion to optimize the microbead diameter at different 
rotational speed.  
3.4.1. Production of microbeads using Polygalacturonic acid 
(PgA) 
PgA solution was prepared within the range 2% to 8% (w/v) in distilled water. This was 
followed by preparation of 100 mM CaCl2 + 0.1%(v/v) Tween-80 solution. The pH of the 
polymer solutions was adjusted to 5 using pH meter. In the experimental setup, the syringe 
was loaded with 200 µl of the polymer solution and centrifuge tube contained the 1.5 ml 
CaCl2 solution. Due to centrifugal force polymer solution came out in a drop by drop 
manner through the 30G needle and crosslinked in CaCl2 solution. The rotation speed was 
varied within a range of 300 rpm to 1900 rpm with an interval of 200 for each 
concentration of PgA solution. 
3.4.2. Production of Alginate (Alg) based microbeads 
2% Alginate solution, 100mM CaCl2 + 0.1% (v/v) Tween-80 solution was prepared in 
distilled water. In the experimental setup, the syringe was loaded with 200 µl of the 
polymer solution and centrifuge tube contained the 1.5 ml CaCl2 solution. Due to 
centrifugal force polymer solution came out in a drop by drop manner through the 30G 
needle and crosslinked in CaCl2 solution. Moreover, the rotational speed-regulated the 
diameter of the microbeads. At 1500 rpm centrifugation speed microbeads were 
synthesized using swinging bucket centrifuge (REMI, 4M). Prepared beads were 
visualized under 10X magnification using an inverted microscope (Zeiss). 
3.4.3. Production of PgA based microbeads at pH 7 to optimize 
microbead diameter at 1500 rpm 
7% and 8% (w/v) PgA solution was prepared in distilled water and pH were adjusted to 7 
using pH meter. This was followed by preparation of 100 mM CaCl2 + 0.1% (v/v) Tween-
80 solution. In the experimental setup, the syringe was loaded with 200 µl of the polymer 
solution and centrifuge tube contained the 1.5 ml CaCl2 solution. Due to centrifugal force 
polymer solution came out in a drop by drop manner through the 30G needle and 
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crosslinked in CaCl2 solution. The rotation speed was maintained at 1500 rpm for both the 
polymer concentration. 
3.4.4. Production of microbeads using various composition of 
Polygalacturonic acid (PgA) and Pectin 
9% and 10% (w/v) solution of Pectin and PgA was prepared and 9% Pectin and PgA 
solution were mixed 1:1 and 1:3 ratio respectively and a similar proportion was also 
maintained for 10% solution of Pectin and PgA. The pH of these solutions was adjusted 
within a range of 7.2-7.4 using pH meter (Systronics). 100 mM CaCl2 solution with 
0.1w% Tween-80 was made to prepare the microbeads because of polymerization in 
CaCl2 Solution. In this experimental setup, the syringe contains 200 µl of the polymer 
solution and centrifuge tube contains the 1.5 ml CaCl2 solution. Due to centrifugal force 
polymer solution come out in a drop by drop manner through 30G needle and crosslinks in 
CaCl2 solution. Moreover, the rotational speed regulates the diameter of the microbeads. 
Hence, three set of experiments were conducted at 1500 rpm, 1700 rpm and 1900 rpm 
using swinging bucket centrifuge (REMI, 4M) to optimize the microbead diameter. 
Prepared beads were visualized under 10X magnification using an inverted microscope 
(Zeiss) and the diameter of beads was determined using ImageJ software. 
3.5. Viscosity measurement 
 
The viscosity of various polymer solution was measured with the help of viscometer. 
3.5.1. Viscosity measurement of PgA solution at various 
concentration 
Viscosity measurement of PgA solution at various concentration: PgA polymer solution 
was prepared within the range 2% to 8% (w/v) in distilled water and pH was adjusted to 5 
using pH meter. The viscosity of each sample was determined using viscometer (BOHLIN 
VISCO).  
3.5.2. Viscosity measurement of Alginate solution at various 
concentration 
Alginate solution was prepared within the range 2% to 6% (w/v) in distilled water. The 
viscosity of each sample was determined using viscometer (BOHLIN VISCO).  
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3.5.3. Viscosity measurement of various composition of  Pectin 
and PgA solution 
9% and 10% (w/v) solution of Pectin and PgA was prepared and 9% Pectin and PgA 
solution were mixed 1:1 and 1:3 ratio respectively and a similar proportion was also 
maintained for 10% solution of Pectin and PgA. The pH of these solutions was adjusted 
within a range of 7.2 to 7.4 using 1 M NaOH. The viscosity of these four samples was 
determined using viscometer (BOHLIN VISCO). 
3.6. Hemolysis assay 
 
For the hemolysis assay, Anticoagulated blood was diluted using 0.9% NaCl 
(physiological saline) in the ratio 8:10, to prepare the stock solution. The beads were 
prepared using 7% and 8% (w/v) PgA concentration (at pH 5) and the combination of 
Pectin and PgA (at 9% as well as 10%) in a ratio 1:1 and 1:3 respectively (at pH 7). The 
microbeads were placed into 15 ml falcon tubes and 0.5 ml of diluted blood was dispensed 
on them. The volume inside the tubes was made up to 10 ml using 0.9 % NaCl. 0.5 ml of 
diluted blood was added in a falcon tube and the volume was made up to 10 ml by using 
saline, and this was taken as the negative control for this experiment. The positive control 
was prepared by adding 0.5 ml of diluted blood and 0.5 ml of 0.01 M HCl and making up 
the volume to 10 ml using saline. All the tubes were centrifuged at 4000 rpm for 10 mins. 
OD of the supernatants was measured at 540 nm with the help of spectrophotometer [36]. 
Hemolysis Percentage was calculated using the following formula: 
  
3.7. Degradation study of microbeads 
Microbeads were prepared using various composition of polymers. Washing of 
microbeads was followed by resuspension of those in PBS for the desired time span to 
check any degradation is occurring or not. 
3.7.1. Degradation study of PgA based microbeads 
7% to 8% (w/v) PgA solution was prepared in distilled water. This was followed by 
preparation of 100 mM CaCl2 + 0.1% (v/v) Tween-80 solution. The pH of the polymer 
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solutions was adjusted to 5 using 2 N NaOH. In the experimental setup, the syringe was 
loaded with 200 µl of the polymer solution and centrifuge tube contained the 1.5 ml CaCl2 
solution. Microbeads were prepared at 1500 rpm speed. Microbeads were visualized under 
10X magnification with the help of inverted microscope (Zeiss). The diameter of 
microbeads was measured using ImageJ software after every 24 hrs. until day 6. 
3.7.2. Degradation study of Pectin and PgA based microbeads 
Microbeads were prepared using 4 different compositions of polymers such as 9% and 
10% (w/v) solution of Pectin and PgA, mixed at 1:1 and 1:3 ratio respectively. After 
crosslinking with CaCl2 microbeads were washed with PBS twice and again re-suspended 
in PBS buffer. The diameter of the microbeads was measured using ImageJ software so 
that it can be concluded that whether microbeads are degrading or not. This study was 
conducted till 14th day after microbeads were prepared. 
3.8. Protein release study 
 
9% and 10% (w/v) solution of Pectin and PgA was prepared and 9% Pectin and PgA 
solution were mixed 1:1 and 1:3 ratio respectively and a similar proportion was also 
maintained for 10% solution of Pectin and PgA. The pH of these solutions was adjusted 
within a range of 6.5 to 7 using 2 N NaOH. BSA concentration was maintained 0.5 mg/ml 
for each composition of the polymer. Microbeads were prepared at 1500 rpm speed [48]. 
Prepared beads were washed with PBS twice and kept in PBS solution to carry out protein 
release study after 5 and 10 hrs of incubation at 37°C. Quantification of protein released 
after 5 and 10 hrs were done using Bradford reagent. 30 µl of the sample was collected 
from those four experimental setups and 800µl of Bradford reagent was added to each set. 
After 5 mins of incubation O.D. was measured at 595 nm using a spectrophotometer. The 
quantity of protein released after 3, 6, 9 and 12 hrs was determined from the standard 
curve (within a range of 1 mg/ml to 0 mg/ml with an interval of 0.25) obtained for BSA 
protein.  
 
3.9. Determination of surface topology of microbeads 
 
Microbeads were prepared using various composition of Pectin and PgA polymer. After 
centrifugation, beads were kept in CaCl2 solution for 15 minutes, so that it can crosslink 
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properly. Microbeads were washed with PBS and kept inside ESEM (Environmental 
Scanning Electron Microscope) chamber to visualize the surface topology of those 
microbeads. Samples were observed at 12000X magnification. Further, some microbeads 
were separated into two halves with the help of surgical blade and needle, to visualize the 
topology of the inner surface of microbeads. 
3.10. FTIR analysis 
 
FTIR analysis of four different samples (Pectin, Polygalacturonic acid, two different 
composition of microbeads) were done. Microbeads were produced using above-
mentioned process, followed by washing and drying in hot air oven at 37°C respectively. 
Samples were in powder form and each of them was mixed with KBr (Potassium 
bromide). A Pellet of that mixture of sample and KBr was obtained using hydraulic press 
which was followed by FTIR (Fourier transform infrared spectroscopy) analysis. 
 
3.11. Cell Culture 
 
Macrophage (RAW 264.7) cell line was purchased from NCCS, Pune. DMEM, Low 
Glucose (Himedia) medium supplemented with 10% FBS (Himedia) and 2% of 
antimitotic antibody (Himedia) was used to culture RAW 264.7 inside the incubator in a 
humidified 37°C, 5% CO2 environment. Cell culture media was replenished after every 3 
days [49].  
Steps which were followed to subculture cells are described below: 
 The medium from T75 flask was aspirated and cells were washed with PBS. 
 Cells were detached from the bottom of the flask with the help of cell scraper.  
 Cells were centrifuged at 750g for 5 mins. 
 The supernatant was aspirated and cells were re-suspended in 1 ml of fresh DMEM 
media. 
 Around 1/3rd of the cells were seeded into a new flask. 
 Newly seeded Macrophages (RAW 264.7) were kept in the incubator to allow 
attachment overnight. 
 Cells were visualized under the microscope after 24 hrs to observe whether the 
subculturing process had been carried out successfully. 
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3.12. Microencapsulation of Macrophages (RAW 264.7) 
 
Microcapsules were synthesized using four different polymer composition like Pectin:PgA 
in 1:1 and 1:3 ratio at 9% (w/v) and 10% (w/v) concentration of Pectin as well as PgA. 
The polymer solution was prepared in distilled water [50]. Macrophages were 
encapsulated in these polysaccharide microbeads at a cell density of 3.8x105 cells/ml. The 
polymer droplets fell into 100 mM calcium chloride solution due to centrifugal force, 
where the PgA crosslinked and formed microbeads. This method produced fine 
microbeads with a mean diameter of 327 µm. The microbeads were kept in CaCl2 solution 
for 5 min to crosslink properly. This step was followed by PBS wash of microbeads twice 
and resuspension of beads in 5ml of complete media. The culture flasks containing 
encapsulated macrophages were kept inside the incubator in a humidified 37°C, 5% CO2 
environment. 
3.13. Determination of encapsulation efficiency 
 
To check encapsulation efficiency cells were burst using trisodium citrate solution and 
heat denaturation. The total cell count before and after encapsulation was measured using 
trypan blue staining procedure. 
3.14. Cell viability test using MTT 
 
The viability of encapsulated cells was determined by MTT assay [51]. Among the 
enzyme-based assays, MTT assay is a most preferred technique to check a number of 
viable cells by determining mitochondrial dehydrogenase activities. The principal of MTT 
assay is based on the cleavage of the yellow-colored tetrazolium salt, 3-(4,5-
dimethylthiazol-2-yl)- 2,5-diphenyl tetrazolium bromide, into a blue-colored formazan 
because of the mitochondrial enzyme of viable cells, succinate-dehydrogenase. A solution 
of MTT (5 mg/mL) was prepared in PBS and sterilized by filtration technique using 0.2 
mm filter. MTT solution was added to each Petri plates, containing encapsulated cells, at 
1/10th the medium volume and incubated for 4 hrs in a 37°C, 5% CO2 incubator. After the 
4 hrs medium was removed carefully with the help of pipette to avoid disruption or 
removal of beads. 1ml DMSO was added to each plate and it was again incubated for 20 
mins. The absorbance of the solution was measured at 595 nm with the help of 
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spectrophotometer [52]. Thus following protocol was followed to test the viability of cells 
until 9 days of encapsulation, after every 48 hrs. 
3.15. Visualization of encapsulated cells under inverted 
microscope 
 
After 4 hrs of incubation from the addition of MTT cells were taken out from the 
incubator and visualized under an inverted microscope. Viable cells were stained purple 
and it was distinguishable under 10X, 20X and 40X magnification, using an inverted 
microscope (Optika). 
3.16. Cell cytotoxicity study using LDH Assay kit 
 
Cell cytotoxicity was measured using LDH assay kit. RAW 264.7 cells were encapsulated 
in the different polymer compositions, by following above-mentioned protocol. After 24 
hrs of incubation 20 µl media from each well of encapsulated cells and control (non-
encapsulated cells) was collected in triplicate manner. For positive control, cells were 
lysed with the help of 10X lysis buffer and after centrifugation 20 µl supernatant was 
collected. Solution 1 and 2 from LDH assay kit was mixed in 4:1 ratio to make the final 
solution and 100 µl was added to each well. After 15 to 20 minutes of incubation in 37°C 
and 5% CO2 incubator, O.D. reading was measured using multi-well plate reader at 340 
nm after every 30 secs until 90 secs. The whole procedure was repeated after every 48 hrs 
until 9 days. 
3.17. Determination of ROS generation using NBT Assay 
 
Encapsulated cells and control (non-encapsulated cells) were seeded in 96 well plate in 
triplicate. After 24 hrs of incubation 100 µl of media was aspirated from each well and 50 
µl of fresh media and 50 µl of NBT working solution was added to each well [53]. In a 
37°C and 5% CO2 incubator, 96 well plate was kept for 2 hrs of incubation. Further, the 
whole solution was aspirated from each well and 140 µl of DMSO was added after proper 
washing of each well. Again, it was incubated for 20 mins before collecting the O.D. 
reading using multi-well plate reader at 620 nm. This whole process was repeated after 
every 42 hrs until 9 days to conduct a time-dependent study. 
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3.18. Visualization of encapsulated cells under confocal 
microscope 
 
RAW 264.7 cells were encapsulated using optimized protocol discussed above. After 5 
days, a fluorescent dye (calcein) was used to stain the live cells present inside the 
microbeads. After aspirating whole media, 100 µl of working solution of calcein was 
added. Cells were visualized under a confocal microscope at 100X magnification after 50 
to 55 mins of incubation. The excitation and emission wavelengths of calcein dye are 495 
nm and 516 nm, respectively. 
 
3.19. Morphological study 
 
The phenotype of activated macrophages can be visually distinguished based upon its 
morphological difference. M1 phenotype looks spherical or oval whereas M2 phenotype is 
more elongated [54]. In this study, macrophages were cultured on a film made of two 
different compositions of Pectin and PgA, 10% (w/v) 1:1 and 1:3 respectively. Cells were 
scraped out after five and seven days of incubation. After that macrophage were kept 
inside the incubator in normal tissue culture plate for ten hours to let it adhere. It was 
visualized using inverted microscope at 100X to check whether any morphological change 
has occurred in presence of anti-inflammatory environment or not. The aspect ratio of 
macrophages, cultured in a different environment was measured to check whether any 
elongation has occurred or not. Thus, the phenotype of macrophages was visually 
determined by studying their morphology.                         
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4.1. Optimization of diameter of PgA based microbeads 
 
Change in rotational speed has a significant effect on change in diameter of microbeads. 
Moreover, the diameter of the microbeads can be controlled by changing the composition 
of the polymer as well as the in centrifugal force. With the increase in polymer 
concentration and rotational speed simultaneously, the diameter of microbeads can be 
decreased. In this experiment, the diameter of optimized spherical microbeads at 1900 
rpm, 8% PgA (w/v) concentration is 229.81±5.255827 µm (Figure 4.2). According to the 
result, the range of 1500 to 1900 rpm can be stated as the optimum speed to produce 
microbeads to encapsulate cells in a proper environment where chances of cell necrosis 
will be very less. The concentration of polymer also plays an important role in this 
technique, with 2% (w/v) concentration at 300 rpm speed the diameter of microbead was 
obtained as 950.88±94.65064 µm (Figure 4.1) which is not suitable for cell encapsulation 
as it is for 8% polymer concentration at 1900 rpm. Thus, the diameter of microbeads was 
optimized by increasing the polymer concentration and rotation speed as depicted in 
(Figure 4.3). 
 
 
Figure 4.1: Microbead synthesized at 300 rpm using 2% PgA (w/v) solution (at pH 5). 
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Figure 4.3: Microbeads formed at (a) 1500 rpm, (b) 1700 rpm, (c) 1900 rpm using 7% 
(w/v) PgA solution (at pH 5); (d) 1500 rpm, (e) 1700 rpm, (f) 1900 rpm using 8% (w/v) 
PgA solution (at pH 5). 
Figure 4.2: Representation of change in diameter of microbeads with respect to change in 
rotational speed and polymer concentration. 
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4.2. Viscosity of Alginate and PgA polymer solution at various 
concentration 
 
The viscosity of this two polymer increased with increase in its concentration. But 
viscosity of PgA at lower concentration (2%, 3%, 4%, 5% w/v) was so low that it was 
beyond the detection level of the viscometer. For PgA viscosity of the solution increased 
with increase in pH up to 5. But beyond that level viscosity dropped down tremendously 
with an increase in pH value which was beyond detection level of the viscometer. If we 
compare the viscosity of the Alginate with PgA it can be stated that Alginate solution at 
lower concentration (2% w/v) is much viscous than PgA solution at that concentration. 
The result is depicted below (Figure 4.4). 
 
 
4.3. Hemocompatibility of PgA based microbeads 
 
The in vitro hemolysis assay was carried out to evaluate the hemocompatibility of 
microbeads synthesized using a different concentration of PgA (Figure 4.5). Hemolysis 
Percentage was much less than 5%. Hence, it can be stated that both the polymers are 
hemocompatible. 
Figure 4.4: Representation of change in viscosity with the change in 
concentration of polymers including Alginate and PgA. 
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4.4. Degradation study of PgA based microbeads 
 
7% and 8 % (w/v) concentration of PgA was used to synthesize microbeads at 1500 rpm 
speed and it was kept in PBS solution for 6 days. A minor reduction in diameter of 
microbeads occurred from day 0 to day 6, as depicted below (Figure 4.6). The diameter of 
microbeads produced using 7% and 8% (w/v) PgA solution, decreased approximately 5.44 
and 2.66 µm respectively, which does not interpret any significant change. 
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Figure 4.6: Representation of change in the diameter of microbeads with respect to time. 
Figure 4.5:  Hemolysis Percentage at different concentration of PgA solution. 
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4.5. PgA based microbeads preparation at pH 7 
 
As discussed before at pH 7 the viscosity of PgA solution dropped down tremendously. 
Microbeads formed using that polymer solution got distorted because of very low 
viscosity (Figure 4.7). Hence, cell encapsulation is not possible in this condition. Because 
animal cells need to be maintained at a pH range of 7.2 to 7.4. However, this microbead 
system using PgA can be used in drug loading purpose where pH 5 is suitable. 
 
4.6. Optimization of diameter of Pectin and PgA based 
microbeads 
 
Change in rotational speed has a significant effect on change in diameter of microbeads. 
Moreover, the diameter of the microbeads can be controlled by changing the composition 
of the polymer as well as the in centrifugal force. With the increase in polymer 
concentration and rotational speed simultaneously, the diameter of microbeads can be 
decreased. But at a very high rotational speed like 1900 rpm the shape of the microbeads 
became distorted (Figure 4.9). In this experiment, the diameter of optimized spherical 
microbeads at 1500 rpm varies from 308 to 346 µm (Figure 4.8). At 1700 rpm the 
diameter of microbeads ranges from 286 to 206 µm (Figure 4.8). But at 1700 rpm 
microbeads were not able to maintain its spherical shape properly. Hence, 1500 rpm can 
be stated as the optimum speed to produce microbeads to encapsulate cells in a proper 
environment where chances of cell necrosis will be very low due to unavailability of 
nutrition and oxygen. 
 
b. a. 
Figure 4.7: Microbeads produced at 1500 rpm using (a) 7% and 
(b) 8% (w/v) Polygalacturonic acid (at pH 7). 
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Figure 4.8: Representation of change in diameter of microbeads with respect to change in 
rotational speed and   polymer composition. 
Figure 4.9: Microbeads produced at (a) 1500 rpm, (b) 1700 rpm, (c) 1900 rpm using polymer 
composition 9% (w/v)( Pectin:PgA at 1:1 ratio); (d) 1500 rpm, (e) 1700 rpm, (f) 1900 rpm 
using polymer composition 9% (w/v)( Pectin:PgA at 1:3 ratio); (g) 1500 rpm, (h) 1700 rpm, 
(i) 1900 rpm using polymer composition 10% (w/v)( Pectin:PgA at 1:1 ratio); (j) 1500 rpm, 
(k) 1700 rpm, (l) 1900 rpm using polymer composition 10% (w/v)( Pectin:PgA at 1:3 ratio). 
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4.7. Viscosity measurement of various composition of Pectin 
and PgA polymer solution 
 
Viscosity increased with increase in polymer concentration, especially when the 
proportion of PgA was more than Pectin, as shown below (Figure 4.10). By analyzing the 
viscosity and diameter of microbeads formed at 1500 rpm using the same composition of 
the polymer, it can be stated that diameter of microbeads reduced with an increase in 
viscosity of the solution. 
 
4.8. Hemocompatibility of Pectin and PgA based microbeads 
 
The in vitro hemolysis assay was carried out to evaluate the hemocompatibility of 
microbeads synthesized using different composition of Pectin and PgA (Figure 4.11). 
Hemolysis Percentage for each composition was much less than 5%. Hence, it can be 
stated that both the polymers are highly hemocompatible and suitable for application in 
chronic wound healing. 
 
 
 
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
9% (1:3) 9% (1:1) 10% (1:3) 10% (1:1)
V
is
co
si
ty
 (
P
a
.s
)
Polymer Concentration (%w/v)
(Pe:Pgua)
Figure 4.10: Representation of change in viscosity with respect to polymer composition. 
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4.9. Production of microbeads using three different 
polysaccharide-based polymers at 1500 rpm speed 
 
Microbeads were synthesized using different types of polysaccharide polymer 
composition including Alginate, PgA and Pectin+PgA. The determined diameter of the 
microbeads depicts that microbeads composed of Alginate have smallest diameter, 
followed by Pectin+PgA and PgA respectively (Figure 4.12). This is because Alginate has 
higher viscosity among those three polymer solutions.  
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Figure 4.12: Microbead production using three different polysaccharide based polymers. 
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Figure 4.11: Hemolysis Percentage of different composition of Pectin and PgA based 
microbeads. 
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4.10. Degradation study of PgA based microbeads 
 
Initially, the diameter of microbeads was almost similar. After fourteen days, a minor 
decrease in diameter occurred for each of four samples. The microbead diameter of the 
sample with polymer composition 10% (w/v) (Pectin:PgA at 1:1 ratio), decreased the most 
and it was approximately decreased by 46 µm.  But the average decrease in diameter size, 
at the end of the experiment, was not more than 35µm (Figure 4.13). Hence, it can be 
concluded that these microbeads would sustain till the chronic wounds get healed. 
 
4.11. Protein release study 
 
Bovine serum albumin (BSA) encapsulated microbeads were incubated at 37°C to 
determine the protein release after 5 and 10 hrs. Experimental results obtained from 
Bradford assay depicted time-dependent study of release of encapsulated protein (Figure 
4.14). The highest degree of protein release was obtained for the 10% polymer 
concentration (with Pectin:PgA = 1:1) as depicted below (Figure 4.14). This might have 
happened because microbeads composed of 10% (1:1) polymer has lowest microbead 
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Figure 4.13: Representation of decrease in diameter of microbeads with respect to time. 
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diameter among those four samples. Since, molecular weight as well as a number of 
amino acids of BSA (66.5kDa, 583 amino acids) is higher than IL-10 (20.52kDa, 178 
amino acids), it can be stated that IL-10 will be secreted out from these microbeads. 
Hence, these microbeads can be used for the treatment of chronic wounds after checking 
its anti-inflammatory properties. 
 
4.12. FTIR Analysis 
 
For pure Pectin sample six significant Peaks were observed at 2932 cm-1 (C-H, stretching), 
1742 cm-1 (C=O, stretching), 1632 cm-1 (C-H, bending), 1443 cm-1 (C-H, bending), 1347 
cm-1 (C-H, bending), 1066 cm-1 (C-O, stretching). Six significant Peaks were also 
observed for pure PgA sample, which includes 2932 cm-1 (C-H, stretching), 1742 cm-1 
(C=O, stretching), 1630 cm-1 (C-H, bending), 1412 cm-1 (O-H, bending), 1334 cm-1 (C-H, 
bending), 1096 cm-1  (C-O, stretching). Whereas in case of microbeads composed of 10% 
(w/v) (Pectin:PgA at 1:1 ratio) five different Peaks were most significant like 1632 cm-1 
(C-H, bending), 1424 cm-1 (O-H, bending), 1106 cm-1 (C-O, stretching) and 1026 cm-1 (C-
O, stretching). Further, six significant Peaks were detected for microbeads composed of 
10% (w/v) (Pectin:PgA at 1:3 ratio) like 2950 cm-1 (C-H, stretching), 1632 cm-1 (C-H, 
bending), 1456 cm-1 (C-H, bending), 1136 cm-1 (C-O, stretching) and 1057 cm-1 (C-O, 
stretching). The breaking of the dimer is consistent for both the samples of microbeads. 
This might have happened during crosslinking with CaCl2.  
Figure 4.14: Representation of protein release study. 
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4.13. Surface topology of Microbeads 
 
Surface topology of microbeads was observed using ESEM (Environmental Scanning 
Electron Microscope). With the change in the composition of the polymer, surface 
topology of microbeads was also changed. Visually, the surface of the composition, 
Pectin:PgA at 1:3 seemed to be more rigid than at 1:1 (Figure 4.17). The inner portion of 
microbead was also visualized at 2000X magnification (Figure 4.16). 
a. b. 
c. d. 
Figure 4.15: Representation of FTIR analysis: (a) Pectin; (b)PgA; (c) Pectin:PgA at 1:1 
ratio, 10% (w/v) and (d) Pectin:PgA at 1:3 ratio, 10% (w/v) 
Figure 4.16: Inner structure of Microbead. 
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4.14. Determination of encapsulation efficiency 
 
The encapsulation efficiency was measured using Trypan Blue staining method. Total no. 
of cells before encapsulation in each polymer composition was 2.15x105 cells/ml, and 
calculated total no. of cells after encapsulation was 1.33x105cells/ml, 1.28x105cells/ml for 
10% (w/v) (Pe:PgA at 1:1 ratio) and 10% (w/v) (Pectin:PgA at 1:3 ratio) respectively 
(Figure 4.18). Hence Percentage encapsulation efficiency for 10% (w/v) (Pectin:PgA at 
1:1 ratio) and 10%(w/v) (Pe:PgA at 1:3 ratio) composition are 61.86% and 59.53% 
respectively. 
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Figure 4.18: Representation of encapsulation efficiency. 
Figure 4.17: Surface topology of Microbeads with different polymer concentration, (a) 9% 
(w/v) ( Pectin:PgA at 1:1 ratio), (b) 9% (w/v) ( Pectin:PgA at 1:3 ratio), (c) 10% (w/v) 
(Pectin:PgA at 1:1 ratio), (d) 9% (w/v) ( Pectin:PgA at 1:3 ratio). 
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4.15. Encapsulation of macrophages 
 
Viable encapsulated cells were observed under a microscope. Only viable cells were 
stained during MTT assay and those were distinguishable under 10X, and 40X 
magnification (Figure 4.19). 1x106cells/ml were encapsulated, using 1ml of the polymer. 
Encapsulated cells were visualized, under the microscope after one, three, five, seven and 
nine days of incubation in a humidified 37°C, 5% CO2 environment. 
Figure 4.19: Visualization of cell proliferation inside microbeads, under 
inverted microscope at 100X magnification (a) Day 1, (b) Day 3, (c) Day 
5, (d) Day 7, (e) Day 9; and 400X magnification (f) Day9. 
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4.16. Viability of encapsulated cells: MTT assay 
 
After 24 hrs, observed cell viability was more in the case of control (non-encapsulated 
cells). But in the case of encapsulated cells amount of viable cells is much lower. This 
might have happened because encapsulation efficiency is not 100%. Hence, many cells 
might have washed away during the encapsulation process. Further, 96 hrs later, MTT 
assay results depict that viability of cells were increased with respect to decreasing in 
diameter of the microbeads. Diameter of microbeads with polymer composition 10% 
(w/v) (Pe:PgA at 1:1 ratio) was lesser than microbeads formed with polymer composition 
9% (w/v) (Pe:PgA at 1:3 ratio) and 10% (w/v) (Pectin:PgA at 1:3 ratio). Hence, the 
highest number of viable cells were observed for microbead diameter 308.8±2.962045 
µm. Thus cell viability was measured with the help of MTT assay on first, third, fifth, 
seventh and ninth day (Figure 4.20).  
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Figure 4.20: Representation of effect on cell viability due to encapsulation. 
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Percentage cell viability differed with respect to change in the polymer composition. The 
highest percentage of viability was observed in the case of 10% (w/v) Pectin:PgA= 1:1, 
which ranges in between seventy to seventy-five percent. This was followed by 9% (w/v) 
Pectin:PgA= 1:1, 10% (w/v) Pectin:PgA= 1:3, and 9% (w/v) Pectin:PgA= 1:3. 
 
4.17. Measurement of cell cytotoxicity: LDH assay 
 
Two major forms of cell death observed in normal condition as well as in disease 
pathologies are necrosis and apoptosis. Permeabilization of the plasma membrane is the 
hallmark of necrotic cells. Moreover, necrosis is caused due to swelling and rupture of 
intracellular organelles and this leads to the breakdown of the entire plasma membrane. 
Hence, intracellular components come out into extracellular space because of impaired 
plasma membrane and cause inflammatory responses. Necrosis of cells can be measured 
with the help of cytotoxicity assays. These assays could be principally divided into two 
categories:  one is based on uptake of Propidium iodide (DNA binding dye), another is 
based on leakage of intracellular components to the extracellular milieu through the 
damaged plasma membrane. Moreover, measurement of the amount of released lactate 
dehydrogenase (LDH) helps us to quantify this particular event. The result (Figure 4.21) 
shows that cytotoxicity level for each composition of the polymer is not at all unhealthy 
for cells. Moreover, the condition is not unpleasant if LDH activity is less than 100 IU/I. 
Hence, the system is fine for further consideration. 
0
10
20
30
40
50
60
70
80
90
 DAY 1 DAY 3 DAY 5 DAY 7 DAY 9
%
 C
el
l 
V
ia
b
il
it
y
 
Number of Days
9%(1:1) 9%(1:3) 10%(1:1) 10%(1:3)
Figure 4.21: Representation of percentage cell viability. 
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4.18. Superoxide assay: NBT reduction 
 
The over-generation of ROS leads to Permanent cell damage by evoking an intracellular 
state of oxidative stress. But indirectly it shows the effect of NADPH oxidase. In this 
assay intense color change means more NADPH oxidase activity of macrophages. Hence, 
it can be used to determine the presence of activated macrophages.  The result (Figure 
4.22) depicts the change of polymer composition has an effect on macrophage activation. 
Since LDH assay results concluded that the microbead system has provide healthy 
environment to the cells, it can be concluded that in this system amount of generated ROS 
will not have any unpleasant effect on cells. 
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Figure 4.22: Representation of cell cytotoxicity level. 
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4.19. Visualization of alive cells inside microbeads 
 
The calcein assay is based on the principle of intracellular esterase activity in alive cells 
which causes the conversion of the cell permeant non-fluorescent calcein AM dye to the 
fluorescent dye. Macrophages were encapsulated in four different compositions of Pectin 
and PgA. Encapsulated macrophages were visualized under the confocal microscope after 
five days of incubation. The average no. of cells per microbead is approximately thirty 
(Figure 4.23). 
Table 4.1: Tabulation of an approximate number of alive cells in each microbead. 
Polymer composition Number of cells in each microbead 
9%(w/v) (Pectin:PgA at 1:1 ratio) 28 ± 6 
9%(w/v) (Pectin:PgA at 1:3 ratio) 27 ± 6 
10%(w/v) (Pectin:PgA at 1:1 ratio) 29 ± 5 
10%(w/v) (Pectin:PgA at 1:3 ratio) 27 ± 5 
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Figure 4.23: Representation of activation of macrophages with respect to polymer 
composition. 
Chapter 4                                                                                            Results and Discussion 
43 
 
 
4.20. Morphological study 
 
Macrophages were cultured on the top of the films, made of the different composition of 
Pectin and PGA. After five and seven days of incubation, cells were observed under an 
inverted microscope to study the morphological changes. For control sample where cells 
were cultured in normal tissue culture plate, macrophages remained un-activated (Figure 
4.24). Whereas macrophages cultured on Pectin and PgA based films elongated after five 
days of incubation and they further elongated until the seventh day (Figure 4.24). The 
aspect ratio was also determined and it was in a range of 1.5 to 2 for control and 4 to 6, 4.5 
to 7.5 for experimental samples after five and seven days respectively (Figure 4.25). This 
result depicts that un-activated macrophages polarize into M2 phenotype in presence of 
Pectin and PgA. 
 
 
Figure 4.24: Visualization of encapsulated macrophages in different composition of 
polymer, (a) 9%(w/v) (Pectin:PgA at 1:1 ratio), (b) 9%(w/v) (Pectin:PgA at 1:3 ratio), (c) 
10%(w/v) (Pectin:PgA at 1:1 ratio), (d) 10% (w/v) (Pectin:PgA at 1:3 ratio) under 
confocal microscope. 
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Figure 4.26: Representation of macrophage elongation with respect to polymer 
composition and time. 
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Figure 4.25: Effect of anti-inflammatory environment on polarization of macrophages: 
Observation on day 5: (a) control, (b) cultured on 10% (w/v)( Pectin:PgA at 1:1 ratio), (c) 
10% (w/v)( Pectin:PgA at 1:3 ratio); observation on day 7: (d) control, (e) culture on 10% 
(w/v)( Pectin:PgA at 1:1 ratio), (f) 10% (w/v)( Pectin:PgA at 1:3 ratio). 
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Chapter 5 
Conclusion 
Complete wound healing requires a balance in between pro-inflammatory and anti-
inflammatory phase to repair the wound bed within the stipulated time. Hence, proper 
polarization of macrophages of required phenotype, according to the stage of wound 
healing is very important. Macrophages can be polarized from un-activated state to 
activated M1 or M2 phenotype in presence of external stimuli. The M1 phenotype can be 
generated by inducing unactivated macrophages in presence of microbial stimuli (e.g., 
Lipopolysaccharides), pro-inflammatory cytokines (e.g., IFNγ, TNF), and growth factors 
(e.g., GM-CSF). On the other hand, the polarization of macrophages to M2 phenotype 
occurs in presence of anti-inflammatory cytokines (e.g., IL 10, IL-4, IL-13), and hormones 
(e.g., secosteroid, glucocorticoid). Therefore, a proper understanding of molecular 
mechanisms and micro-environmental stimuli, involved in macrophage polarization would 
permit us to manipulate as well as to regulate those specific physiological processes, 
which are involved in chronic wound healing.  
The introduction of M2 macrophages at the site of chronic wound seems an effective 
strategy to treat chronic wounds since they play a key role in modulating inflammatory 
responses. Major challenges in implementing such strategy are prevention of macrophages 
from washing out from the site of injury, avoiding any immunological reaction due to the 
incorporation of foreign cells, and sustenance of macrophage phenotype over the period of 
healing. Hence, microbead-based technology is an effective strategy for 
immunomodulation of chronic wounds and its early resolution. 
Pectin and PgA based microbeads can be used to encapsulate cells. The centrifuge tube-
syringe setup can be used produce microbeads, having the desired diameter for the 
purpose of cell encapsulation. This is a very cost effective method where centrifugal force 
plays an important role in the production of microbeads. The rotational speed of 1500 rpm 
can be stated as an optimized parameter to synthesize microbeads having a diameter less 
than 350 µm.  
Cells maintained proper viability in an efficient manner within this range of microbead 
diameter. Since, very few cell death occurs in this environment, it can be inferred that 
Chapter 5                                                                                                             Conclusion 
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microbeads provided proper availability of nutrition and oxygen supply. Pectin and PgA 
based microbeads do not hinder cell proliferation and this macrophage-microbead system 
remained stable for more than a week.  
Pectin and PgA are found to be highly hemocompatible in nature. These polysaccharide 
based polymers do not have any cytotoxic effect on the cells when used for the purpose of 
encapsulation. Further, encapsulation of macrophages in Pectin and PgA based 
microbeads might help the un-activated macrophages to polarize in M2 phenotype due to 
anti-inflammatory property of these polysaccharides. Thus, chronic wounds might get 
healed within lesser time span by following proposed strategy. 
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